… pathways could provide an effective anticancer strategy, and a recent preclinical study
showed a synergistic antitumor effect of the erlotinib-sorafenib combination in lung and colorectal …

… non-small cell lung cancer. The aim of the present study was to investigate whether erlotinib
… In the present study, the molecular probe JC-1 was used to detect the effects of erlotinib on …

… Our targeted effect size, ie, an average tumor shrinkage with erlotinib plus sorafenib that is …
patients with renal cell cancer (compared with a small average increase under erlotinib alone)…

… whether an erlotinib-based nanoagent could potentiate Erlotinib to EGFR-wt NSCLC. Towards
this goal, we started exploring how nano-engineering affects the sensitivity of Erlotinib to …

… with erlotinib increases the inhibitory effects of erlotinib alone on NSCLC cell survival and
… Collectively, these results suggest that EFGR inhibitors such as gefitinib and erlotinib, when …

… A profound predictive effect on PFS of erlotinib relative to placebo was observed in the
EGFR mutation–positive subgroup (hazard ratio [HR], 0.10; P < .001). Significant PFS benefits …

… Our data confirmed the effect with the use of erlotinib on recurrent or progressive brain
metastases from NSCLC, an observation that supported the results of some individual case or …

… lung cancer continues to rise. The two main classification of lung cancer based on tumor
histology are small cell lung … evaluated the effects of compound 968 combined with erlotinib on …

… These effects were documented regardless of whether erlotinib was given before, during
or after the chemotherapy agent. Further studies suggested that treatment with …

… In this article, we summarize current data of clinical trials with EGFR TKIs, especially erlotinib,
for advanced NSCLC and discuss its impact on treatment algorithms in advanced NSCLC. …